Patents by Inventor Jonathan Baell
Jonathan Baell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260327237Abstract: This disclosure provides chemical entities (e.g., a compound, or a pharmaceutically acceptable salt thereof) that modulate (e.g., agonize or partially agonize or antagonize) G-protein coupled receptor 52 (sometimes referred to herein as “GPR52”). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GPR52 activity is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition (e.g., a psychiatric disorder, e.g., schizophrenia). In some embodiments, the modulation results in enhancement of (e.g., increases) existing levels (e.g., normal or below normal levels) of GPR52 activity. In some embodiments, the chemical entities described herein further modulate (e.g., increase) ?-arrestin recruitment to GPR52 relative to what is observed with the native ligand.Type: ApplicationFiled: April 1, 2026Publication date: October 22, 2026Inventors: Paul Stupple, Michelle Camerino, YIva Bozikis, Trang Pham, David Shackleford, Christopher Langmead, Gregory Stewart, Jonathan Baell, David C. Tully, Patrick S. Lee, Christopher R. Smith
-
Patent number: 12630541Abstract: Inhibitors of ALCAT1 are described having the general formula: (I). These compounds offer a treatment for aging and age-related diseases.Type: GrantFiled: September 29, 2021Date of Patent: May 19, 2026Assignee: PERENNA PHARMACEUTICALS, INC.Inventors: Yuguang Shi, Daqing Che, Jonathan Baell, Xiaoyu Liu, Jiasheng Fu
-
Publication number: 20220089582Abstract: Inhibitors of ALCAT1 are described having the general formula: (I). These compounds offer a treatment for aging and age-related diseases.Type: ApplicationFiled: September 29, 2021Publication date: March 24, 2022Inventors: Yuguang SHI, Daqing CHE, Jonathan BAELL, Xiaoyu LIU, Jiasheng FU
-
Patent number: 11208404Abstract: Inhibitors of ALCAT1 are described having the general formula: (I). These compounds offer a treatment for aging and age-related diseases.Type: GrantFiled: March 29, 2018Date of Patent: December 28, 2021Assignee: PERENNA PHARMACEUTICALS, INC.Inventors: Yuguang Shi, Daqing Che, Jonathan Baell, Xiaoyu Liu, Jiasheng Fu
-
Patent number: 10829446Abstract: Compound of formula I: wherein: A is selected from: (i) where RF1 is H or F; (ii) (iii) a N-containing C6 heteroaryl group; and B is where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected from H, Me, Cl, F OMe; X3 is either CH or N; X4 is either CRF3 or N, where RF3 is H or F; where only one or two of X1, X2, X3 and X4 may be N; and R4 is selected from I, optionally substituted phenyl, optionally substituted C5-6 heteroaryl; optionally substituted C1-6 alkyl and optionally substituted C1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.Type: GrantFiled: June 9, 2016Date of Patent: November 10, 2020Assignees: MONASH UNIVERSITY, The Walter and Eliza Hall Institute of Medical ResearchInventors: Anne Kathrin Voss, Jonathan Baell, Huu Nghi Nguyen, David J. Leaver, Benjamin L. Cleary, H. Rachel Lagiakos, Bilal Nadeem Sheikh, Timothy John Thomas
-
Publication number: 20200109136Abstract: Inhibitors of ALCAT1 are described having the general formula: (I). These compounds offer a treatment for aging and age-related diseases.Type: ApplicationFiled: March 29, 2018Publication date: April 9, 2020Inventors: Yuguang SHI, Daqing CHE, Jonathan BAELL, Xiaoyu LIU, Jiasheng FU
-
Publication number: 20180222857Abstract: Compound of formula I: wherein: A is selected from: (i) where RF1 is H or F; (ii) (iii) a N-containing C6 heteroaryl group; and B is where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected from H, Me, Cl, F OMe; X3 is either CH or N; X4 is either CRF3 or N, where RF3 is H or F; where only one or two of X1, X2, X3 and X4 may be N; and R4 is selected from I, optionally substituted phenyl, optionally substituted C5-6 heteroaryl; optionally substituted C1-6 alkyl and optionally substituted C1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.Type: ApplicationFiled: June 9, 2016Publication date: August 9, 2018Applicants: MONASH UNIVERSITY, The Walter and Eliza Hall Institute of Medical ResearchInventors: Anne Kathrin VOSS, Jonathan BAELL, Huu Nghi NGUYEN, David J. LEAVER, Benjamin L. CLEARY, H. Rachel LAGIAKOS, Bilal Nadeem SHEIKH, Timothy John THOMAS
-
Patent number: 7956216Abstract: Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.Type: GrantFiled: December 21, 2006Date of Patent: June 7, 2011Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Guillaume Laurent Lessene, Jonathan Baell
-
Publication number: 20080153802Abstract: Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.Type: ApplicationFiled: December 21, 2006Publication date: June 26, 2008Applicant: THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCHInventors: Guillaume Laurent Lessene, Jonathan Baell
-
Publication number: 20070197430Abstract: Conformationally constrained peptides that mimic BH3-only proteins and their conjugation to antibodies and other cell targeting compounds, compositions containing the conjugates and their use in the regulation of cell death are disclosed. The conformationally constrained peptides are capable of binding to and neutralising pro-survival Bcl-2 proteins. Processes for preparing the conformationally constrained peptides conjugated to antibodies and other cell targeting compounds and use of the conjugates in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also disclosed.Type: ApplicationFiled: June 24, 2005Publication date: August 23, 2007Inventors: Jonathan Baell, Andrew Wei, Denis Scanlon
-
Publication number: 20070032417Abstract: Conformationally constrained peptides that mimic BH3-only proteins, compositions containing them and their use in the regulation of cell death are disclosed. The conformationally constrained peptides are capable of binding to and neutralising pro-survival Bcl-2 proteins. Processes for preparing the conformationally constrained peptides and their use in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also disclosed.Type: ApplicationFiled: December 24, 2003Publication date: February 8, 2007Applicant: Walter and Eliza Hall Institute of Medical ResearchInventor: Jonathan Baell
-
Publication number: 20060057144Abstract: This invention relates to a method of inhibiting FC receptor binding of immunoglobulin comprising the use of a Fc receptor modulating compound which binds to defined surfaces on a Fc receptor. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.Type: ApplicationFiled: June 3, 2004Publication date: March 16, 2006Inventors: Jonathan Baell, Thomas Garrett, P. Hogarth, Barry Matthews, Thomas McCarthy, Geoffrey Pietersz, Maree Powell, Ian McKenzie, Kelly Maxwell, Vidana Epa
-
Publication number: 20050261301Abstract: Various divalent ligands based on khellinone derivatives are described. These derivatives can be useful in the modulation of potassium channel activity in cells, including among others Kv1.3 channels found in T-cells. The compounds may also be useful in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis.Type: ApplicationFiled: March 20, 2003Publication date: November 24, 2005Inventors: Jonathan Baell, Heike Wulff, Andrew Harvey, Raymond Norton, George Chandy
-
Publication number: 20050176813Abstract: Various chalcone derivatives of the general formula (I) are described and the variables, A, B, m and R1 to R10 are as defined in the specification. These derivatives can be useful in the modulation of potassium channel activity in cells and may be useful in the treatment or prevention of autoimmune and inflammatory diseases.Type: ApplicationFiled: March 14, 2003Publication date: August 11, 2005Inventors: Jonathan Baell, Heike Wulff, George Chandy, Raymond Norton